These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 36960215)
21. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242 [TBL] [Abstract][Full Text] [Related]
22. Gasdermin-B promotes invasion and metastasis in breast cancer cells. Hergueta-Redondo M; Sarrió D; Molina-Crespo Á; Megias D; Mota A; Rojo-Sebastian A; García-Sanz P; Morales S; Abril S; Cano A; Peinado H; Moreno-Bueno G PLoS One; 2014; 9(3):e90099. PubMed ID: 24675552 [TBL] [Abstract][Full Text] [Related]
23. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade. Yang Q; Ni L; Imani S; Xiang Z; Hai R; Ding R; Fu S; Wu JB; Wen Q Cancer Manag Res; 2020; 12():4937-4948. PubMed ID: 32606981 [TBL] [Abstract][Full Text] [Related]
24. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway. Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131 [TBL] [Abstract][Full Text] [Related]
25. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma. Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116 [TBL] [Abstract][Full Text] [Related]
26. Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe. Deng Z; Liao W; Wei W; Zhong G; He C; Zhang H; Liu Q; Xu X; Liang J; Liu Z Cancer Cell Int; 2021 Jan; 21(1):37. PubMed ID: 33422069 [TBL] [Abstract][Full Text] [Related]
27. Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis. Zhang X; Zhang P; An L; Sun N; Peng L; Tang W; Ma D; Chen J Acta Pharm Sin B; 2020 Aug; 10(8):1397-1413. PubMed ID: 32963939 [TBL] [Abstract][Full Text] [Related]
28. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer. Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567 [TBL] [Abstract][Full Text] [Related]
29. Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis. Zhen H; Tian J; Li G; Zhao P; Zhang Y; Che J; Cao B BMC Cancer; 2023 Mar; 23(1):207. PubMed ID: 36870981 [TBL] [Abstract][Full Text] [Related]
30. Anti-cancer Drug Anlotinib Promotes Autophagy and Apoptosis in Breast Cancer. Chen S; Gao Y; Zhu P; Wang X; Zeng L; Jin Y; Zhi X; Yang H; Zhou P Front Biosci (Landmark Ed); 2022 Apr; 27(4):125. PubMed ID: 35468684 [TBL] [Abstract][Full Text] [Related]
31. The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer. Zheng W; Sun G; Li Z; Wu F; Sun G; Cao H; Zhou J; Ma Y Front Surg; 2022; 9():895982. PubMed ID: 35495754 [TBL] [Abstract][Full Text] [Related]
32. Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway. Chen Q; Lai Q; Jiang Y; Yao J; Chen Q; Zhang L; Wang C; Zhou Y; Deng M; Xu B Transl Oncol; 2022 Nov; 25():101516. PubMed ID: 35985203 [TBL] [Abstract][Full Text] [Related]
33. Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness. Molina-Crespo Á; Cadete A; Sarrio D; Gámez-Chiachio M; Martinez L; Chao K; Olivera A; Gonella A; Díaz E; Palacios J; Dhal PK; Besev M; Rodríguez-Serrano M; García Bermejo ML; Triviño JC; Cano A; García-Fuentes M; Herzberg O; Torres D; Alonso MJ; Moreno-Bueno G Clin Cancer Res; 2019 Aug; 25(15):4846-4858. PubMed ID: 31064780 [TBL] [Abstract][Full Text] [Related]
34. Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab. Liu Z; Qin T; Yuan X; Yang J; Shi W; Zhang X; Jia Y; Liu S; Wang J; Li K Front Oncol; 2022; 12():875888. PubMed ID: 35664796 [TBL] [Abstract][Full Text] [Related]
35. Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib. Sun X; Shu Y; Yan P; Huang H; Gao R; Xu M; Lu L; Tian J; Huang D; Zhang J Cell Death Dis; 2020 Aug; 11(8):702. PubMed ID: 32839434 [TBL] [Abstract][Full Text] [Related]
36. Apoptotic caspase-7 activation inhibits non-canonical pyroptosis by GSDMB cleavage. Li X; Zhang T; Kang L; Xin R; Sun M; Chen Q; Pei J; Chen Q; Gao X; Lin Z Cell Death Differ; 2023 Sep; 30(9):2120-2134. PubMed ID: 37591921 [TBL] [Abstract][Full Text] [Related]
37. Gasdermin B (GSDMB) in psoriatic patients-a preliminary comprehensive study on human serum, urine and skin. Nowowiejska J; Baran A; Pryczynicz A; Hermanowicz JM; Sieklucka B; Pawlak D; Flisiak I Front Mol Biosci; 2024; 11():1382069. PubMed ID: 38693919 [TBL] [Abstract][Full Text] [Related]
38. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity. Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683 [TBL] [Abstract][Full Text] [Related]
39. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells. Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383 [TBL] [Abstract][Full Text] [Related]
40. A pan-cancer analysis of molecular characteristics and oncogenic role of gasdermins. Mu M; Yu Q; Zhang Q; Guo J; Wang X; Sun X; Yu J Cancer Cell Int; 2022 Feb; 22(1):80. PubMed ID: 35164740 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]